Jacek Mackiewicz

Jacek Mackiewicz

Poznan University of Medical Sciences - Poznan / Poland
Others
AD Scientific Index ID: 1828895
Karol Marcinkowski University of Medical Sciences in Poznan
person_outline Jacek Mackiewicz's MOST POPULAR ARTICLES
1-) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanomaA Ribas, R Kefford, MA Marshall, CJA Punt, JB Haanen, M Marmol, ...Journal of clinical oncology 31 (5), 616, 20138242013
2-) Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trialJJ Luke, P Rutkowski, P Queirolo, M Del Vecchio, J Mackiewicz, ...The Lancet 399 (10336), 1718-1729, 20221802022
3-) Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients …SJ O\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'Day, AMM Eggermont, V Chiarion-Sileni, R Kefford, JJ Grob, ...Journal of Clinical Oncology 31 (9), 1211-1218, 20131802013
4-) Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerCE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ...Annals of oncology 33 (12), 1250-1268, 20222452022
5-) Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25D Hannani, M Vetizou, D Enot, S Rusakiewicz, N Chaput, D Klatzmann, ...Cell research 25 (2), 208-224, 20151982015